2023 Interpreting Data from Dose-Finding Studies in Early Phase Oncology Trials to Determine the Optimal Dose View PDF
2023 Incorporating Pragmatic Elements in Study Designs to Enhance Oncology Randomized Clinical Trials View PDF
Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: Initial findings from a retrospective aggregate analysis of 8 clinical trials View PDF
Real-world response endpoints in patients with mNSCLC treated with chemotherapy across real-world datasets View PDF
2023 Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials. Read more
2022 Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials Read more
